In postmenopausal women with osteoporosis, 2 doses of zoledronate 5 mg at an approximately 6-year interval prevented bone loss for almost 11 years.
Tramadol use is associated with increased risk for hip fracture compared with other commonly prescribed pain medications.
The Endocrine Society has issued an update to the organization’s 2019 clinical practice guideline on pharmacologic management of osteoporosis to include romosozumab.
Women with osteoporosis and a history of vertebral fractures had improved balance and muscle strength and reduced fear of falling after participation in a supervised, multicomponent balance and resistance exercise program.
Red cell distribution width values are associated with risk for fracture in older men, particularly those with anemia.
Oral bisphosphonate treatment was not associated with increased all-cause mortality risk in patients with moderate to severe chronic kidney disease.
In patients with axial spondyloarthritis, use of lateral DXA, as opposed to the conventional anteroposterior projection, significantly increased the prevalence of low BMD measurements.
The use of calcium dietary supplements was found to be associated with slower decline in femoral neck and lumbar spine bone mineral density across the menopausal transition.
A study found that patients with anorexia nervosa have a particularly high risk for hip, vertebral, and upper arm fractures.
Researchers examined the association between delays in injections of denosumab and bone mineral density change.
In older adults, no significant changes in bone strength or structure were noted after 2 years of daily vitamin D supplementation.